Moving Beyond Directly Observed Therapy for Tuberculosis

PLoS Medicine

Volumn 12, Issue 9, 2015, Pages

  Metcalfe, John Z ^a   O’Donnell, Max R ^b   Bangsberg, David R ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Medicine   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; COMMUNITY CARE; DIRECTLY OBSERVED THERAPY; EPIDEMIC; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CENTER; HUMAN; SHORT COURSE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT REFUSAL; TUBERCULOSIS; ANTIBIOTIC RESISTANCE; MEDICATION COMPLIANCE;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, BACTERIAL; HUMANS; MEDICATION ADHERENCE; TUBERCULOSIS;

EID: 84943176850     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001877     Document Type: Article

References (24)

1. Selkon JB, Devadatta S, Kulkarni KG, Mitchison DA, Narayana AS, Nair CN, et al. The Emergence of Isoniazid-Resistant Cultures in Patients with Pulmonary Tuberculosis during Treatment with Isoniazid Alone or Isoniazid Plus Pas. Bull World Health Organ. 1964;31:273–94. 14253244
2. Yeager RL, Munroe WG, Dessau FI, Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. American review of tuberculosis. 1952;65(5):523–46. 14924175
3. Vall-Spinosa A, Lester W, Moulding T, Davidson PT, McClatchy JK, Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections. N Engl J Med. 1970;283(12):616–21. 4988918
4. Lee M, Cho SN, Barry CE, 3rdSong T, Kim Y, Jeong I, Linezolid for XDR-TB—Final Study Outcomes. N Engl J Med. 2015;373(3):290–1. doi: 10.1056/NEJMc1500286 26176401
5. Chaisson RE, Coberly JS, De Cock KM, DOTS and drug resistance: a silver lining to a darkening cloud. Int J Tuberc Lung Dis. 1999;3(1):1–3. 10094162
6. Bayer R, Wilkinson D, Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995;345(8964):1545–8. 7677849
7. World Health Organization Global Tuberculosis Programme. Framework for effective tuberculosis control. WHO/TB/94.179. Geneva; WHO, 1994.
8. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW, The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993;328(8):521–6. 8381207
9. Duda SN, Farr AM, Lindegren ML, Blevins M, Wester CW, Wools-Kaloustian K, et al. Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration. J Int AIDS Soc. 2014;17:19045. doi: 10.7448/IAS.17.1.19045 25516092
10. Annas GJ, Control of tuberculosis—the law and the public's health. N Engl J Med. 1993;328(8):585–8. 8426636
11. Sagbakken M, Frich JC, Bjune GA, Porter JD, Ethical aspects of directly observed treatment for tuberculosis: a cross-cultural comparison. BMC Med Ethics. 2013;14:25. doi: 10.1186/1472-6939-14-25 23819555
12. Daftary A, Padayatchi N, O'Donnell M, Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. Glob Public Health. 2014;9(9):1107–16. doi: 10.1080/17441692.2014.934266 25035943
13. Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11(2):167–74. 21406048
14. van den Boogaard J, Boeree MJ, Kibiki GS, Aarnoutse RE, The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out? Trop Med Int Health. 2011;16(6):693–8. doi: 10.1111/j.1365-3156.2011.02755.x 21375681
15. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330(17):1179–84. 8139628
16. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E, Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis. 1999;3(1):4–11. 10094163
17. Volmink J, Garner P, Directly observed therapy for treating tuberculosis. The Cochrane database of systematic reviews. 2007;(4):CD003343. 17943789
18. Pope DS, Chaisson RE, TB treatment: as simple as DOT? Int J Tuberc Lung Dis. 2003;7(7):611–5. 12870680
19. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T, Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011;204(12):1951–9. doi: 10.1093/infdis/jir658 22021624
20. Ankomah P, Levin BR, Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS Pathog. 2012;8(1):e1002487. doi: 10.1371/journal.ppat.1002487 22253599
21. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR, JrTreatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328(8):527–32. 8426619
22. Bangsberg DR, Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197 Suppl 3:S272–8. doi: 10.1086/533415 18447613
23. Petersen ML, LeDell E, Schwab J, Sarovar V, Gross R, Reynolds N, et al. Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring. J Acquir Immune Defic Syndr. 2015;69(1):109–18. doi: 10.1097/QAI.0000000000000548 25942462
24. Curry FJ, Encounters in training clinic support staff. Chest. 1975;68(3 Suppl):462–5. 1157565